Key result
Cotreatment with aliskiren and valsartan markedly reduced oxidative stress, glomerular collapse, and interstitial tissue expansion compared with aliskiren monotherapy in rats.
Why the study?
Does the combination of aliskiren and valsartan improve hypertensive nephropathy in L-NAME treated rats compared to monotherapy?
Does the combination of aliskiren and valsartan improve hypertensive nephropathy in L-NAME treated rats compared to monotherapy?
Combination therapy with aliskiren and valsartan provides additive renoprotective effects against structural injury in experimental hypertensive nephropathy.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for additive renoprotection in hypertensive nephropathy models; leaves open clinical translation beyond monotherapy.
Neither ACEI nor ARBs completely repress the RAAS. Aliskiren is a newer agent that inhibits renin. However, it increases the biosynthesis and secretion of renin and prorenin, that might induce renal tissue damage. This study was conducted to investigate the renoprotective effects of aliskiren and valsartan the ARB, either alone or in combination, on hypertensive nephropathy induced by L-NAME. Aliskiren (50 mg/kg/daily i.p.), valsartan (10 mg/kg daily i.p.) alone or in half dose combination were administered with L-NAME (30-40 mg daily in drinking water) for 8 weeks. Aliskiren and valsartan significantly reduced systolic blood pressure, proteinuria, serum creatinine, blood urea nitrogen, oxidative stress, and structural renal injury although not to the same extent. Valsartan reduced systolic blood pressure and proteinuria in L-NAME treated rats more significantly than aliskiren. However, glomerular collapse index and the expansion of interstitial tissue were significantly attenuated by aliskiren than by valsartan. Cotreatment with aliskiren and valsartan markedly reduced the oxidative stress and further reduced the glomerular collapse and the expansion of interstitial tissue compared with aliskiren monotherapy. CONCLUSION: These results suggest that therapies aimed at different targets within the RAAS may have additional effects in attenuating structural injury in experimental hypertensive nephropathy.
No takes yet. Share an insight, caveat, or question.
Hala Salah Abdel Kawy (2017) studied Hypertensive nephropathy. Aliskiren and valsartan combination vs. Aliskiren monotherapy and valsartan monotherapy was evaluated on Systolic blood pressure, proteinuria, oxidative stress, and structural renal injury. Cotreatment with aliskiren and valsartan markedly reduced oxidative stress, glomerular collapse, and interstitial tissue expansion compared with aliskiren monotherapy in rats.
Synapse has enriched 10 related papers. Consider them for comparative context: